StoryFunding
Life Biosciences completes an $82M Series C to advance its reprogramming and aging programs
Life Biosciences closed an $82 million Series C led by Alpha Wave Ventures, taking total funding past $158 million, to advance its three aging-biology platforms toward first-in-human studies. Platforms target mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming, each addressing different age-related diseases.
- Series C of $82 million led by Alpha Wave Ventures brings total funding to over $158 million.
- Three therapeutic platforms: mitochondrial uncoupling, chaperone-mediated autophagy, epigenetic reprogramming.
- CEO Jerry McLaughlin expected first-in-human studies possibly as early as end of 2022.
- Each platform targets different aging mechanisms and associated age-related conditions.